ITN/JDRF Partnership Program

The JDRF/ITN Partnership in Immune Tolerance Program supports early stage clinical development of tolerogenic protocols in Type 1 diabetes. The initiative aims to facilitate the development of novel tolerance agents in type 1 diabetes by targeted funding available through a fast-turnaround, streamlined application process administered by the ITN, with JDRF participation.

In particular, this initiative aims to foster the development of partnerships between academia and industry in order to bridge early clinical studies of therapies that have strong preclinical evidence for efficacy by supporting drug development and pre-clinical toxicology, phase 1 safety trials and small human efficacy trials that will provide proof-of-principle in well controlled, safe settings.

Examples of research that will be considered for support under this program:

• therapeutic strategies aimed at promoting immune tolerance in new/early onset type 1 diabetes
• therapeutic strategies aimed at promoting immune tolerance in established type 1 diabetes
• interventions aimed at restoring/reconstituting beta cell function without long term immunosuppression

Research that is outside the scope of this initiative:

• any animal studies not directly related to toxicology or pharmacodynamics in preparation of human clinical studies
• studies in Type 2 diabetes or gestational diabetes are not eligible for funding.
• type 1 diabetes prevention studies will not be considered - these should be submitted to the ITN or TrialNet as regular Concept Proposals

Applications for support are accepted year-round, with no application deadlines. To apply, complete the application template forms below and submit online through this site.